After yesterday's big rally, markets are mixed on relatively light volatility heading into the afternoon. Two of the three major indexes have held on to their gains and all appear poised to finish the week in positive territory.
After the Dow Jones Industrial Average's
What do investors have to thank for the support? Continued and increasing confidence of a Greek debt deal getting finalized and improvement in the U.S. economy, as seen in yesterday's positive housing and unemployment data. Furthermore, Congress doesn't appear determined to sabotage a recovery and in a show of bipartisanship passed an extension of the payroll tax cuts and jobless benefits through 2012.
Several other high-profile movers today include popular biotech Cell Therapeutics
On the other hand, Pixuvri is not a first-line treatment, so although competitor Spectrum Pharmaceuticals
A better approach
Watching the broad market each day can be exciting, gut-wrenching, and stressful. If you're in the mood to pick up a great company to buy for the long term, though, The Motley Fool has created a brand-new free report: "The Motley Fool's Top Stock for 2012." It features a company hand-selected by the Fool's chief investment officer that has a strong future ahead of it. I invite you to take a copy, free for a limited time. Get access to the report and find out the name of this legendary company. The report is free, but won't be forever, so check it out today.
David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.